GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
J

Jiangsu Kanion Pharmaceutical Co 600557.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

12.56

-1.34%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥3.29bn

FY2016FY2025

Net income

CN¥303.9m

FY2016FY2025

Free cash flow

CN¥88.8m

FY2016FY2025

Shareholders' equity

CN¥4.82bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥3.29bnCN¥3.90bnCN¥4.86bnCN¥4.35bnCN¥3.65bnCN¥3.03bnCN¥4.57bnCN¥3.82bnCN¥3.27bnCN¥3.00bn
Gross profitCN¥2.35bnCN¥2.83bnCN¥3.61bnCN¥3.14bnCN¥2.63bnCN¥2.21bnCN¥3.56bnCN¥2.92bnCN¥2.48bnCN¥2.24bn
Research and developmentCN¥607.6mCN¥638.1mCN¥847.0mCN¥605.7mCN¥499.4mCN¥380.4mCN¥442.6mCN¥289.7mCN¥236.6mCN¥361.8m
Operating incomeCN¥375.0mCN¥384.5mCN¥460.8mCN¥454.8mCN¥351.0mCN¥351.4mCN¥578.9mCN¥483.5mCN¥442.0mCN¥386.8m
Net incomeCN¥303.9mCN¥391.9mCN¥464.2mCN¥434.5mCN¥320.5mCN¥262.9mCN¥507.0mCN¥414.1mCN¥373.8mCN¥373.7m
Diluted earnings per share0.530.680.810.730.570.390.870.700.700.60

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥6.86bnCN¥6.91bnCN¥7.12bnCN¥6.80bnCN¥6.02bnCN¥6.12bnCN¥6.11bnCN¥5.60bnCN¥5.39bnCN¥4.73bn
Cash and short-term investments—CN¥2.24bnCN¥2.43bnCN¥1.77bnCN¥1.11bnCN¥773.3mCN¥409.0mCN¥378.2mCN¥295.3mCN¥248.4m
Total liabilitiesCN¥1.85bnCN¥2.20bnCN¥1.74bnCN¥1.86bnCN¥1.55bnCN¥1.79bnCN¥2.02bnCN¥1.71bnCN¥1.80bnCN¥1.52bn
Debt—CN¥548.0mCN¥1.9mCN¥11.9mCN¥234.5mCN¥488.0mCN¥685.0mCN¥635.0mCN¥680.2mCN¥274.9m
Shareholders' equityCN¥4.82bnCN¥4.51bnCN¥5.19bnCN¥4.75bnCN¥4.30bnCN¥4.17bnCN¥3.94bnCN¥3.89bnCN¥3.49bnCN¥3.14bn
Shares outstanding572m577m573m595m564m682m580m589m530m620m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥610.6mCN¥702.5mCN¥972.3mCN¥995.9mCN¥908.3mCN¥701.1mCN¥925.7mCN¥636.4mCN¥382.9mCN¥299.0m
Capital spending−CN¥521.8m−CN¥476.7m−CN¥297.5m−CN¥211.1m−CN¥171.5m−CN¥190.3m−CN¥490.1m−CN¥315.7m−CN¥260.9m−CN¥325.2m
Free cash flowCN¥88.8mCN¥225.8mCN¥674.8mCN¥784.9mCN¥736.8mCN¥510.8mCN¥435.7mCN¥320.7mCN¥122.0m−CN¥26.2m
Dividends paid−CN¥91.9m−CN¥213.6m−CN¥128.5m−CN¥2.5m−CN¥11.1m−CN¥47.4m−CN¥47.4m−CN¥37.0m−CN¥90.1m−CN¥60.0m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥830.2mCN¥831.3mCN¥950.2mCN¥701.1mCN¥764.0mCN¥877.6mCN¥788.1mCN¥849.0m
Gross profitCN¥588.2mCN¥623.2mCN¥725.2mCN¥463.8mCN¥512.6mCN¥651.0mCN¥525.7mCN¥622.4m
Operating incomeCN¥77.3mCN¥96.6mCN¥124.7mCN¥75.4mCN¥80.3mCN¥104.3m−CN¥37.8mCN¥82.8m
Net incomeCN¥67.9mCN¥79.3mCN¥104.3mCN¥57.3mCN¥59.0mCN¥83.4mCN¥34.7mCN¥72.4m
Diluted earnings per share0.120.140.180.100.100.150.060.13
Cash from operations———CN¥201.0mCN¥67.0mCN¥76.0mCN¥94.0mCN¥216.0m
Capital spending−CN¥99.0m−CN¥187.0m−CN¥186.0m−CN¥128.0m−CN¥110.0m−CN¥96.0m−CN¥166.0m−CN¥78.0m
Free cash flow———CN¥73.0m−CN¥43.0m−CN¥20.0m−CN¥72.0mCN¥138.0m
Total assetsCN¥6.97bnCN¥6.89bnCN¥6.86bnCN¥6.74bnCN¥6.83bnCN¥6.88bnCN¥6.91bnCN¥6.90bn
Cash and short-term investments———CN¥2.16bnCN¥2.08bnCN¥2.14bnCN¥2.24bnCN¥2.14bn
Debt———CN¥43.2m—CN¥103.9mCN¥548.0m—
Shareholders' equityCN¥4.97bnCN¥4.90bnCN¥4.82bnCN¥4.71bnCN¥4.66bnCN¥4.60bnCN¥4.51bnCN¥5.15bn

Financial ratios

Data as of 9 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Gross margin71.4%72.7%74.2%72.1%71.9%73.0%——
Operating margin11.3%10.5%9.2%10.3%9.3%10.5%——
Net margin9.2%10.1%9.5%10.0%8.8%8.7%——
Return on equity6.3%8.7%8.9%9.1%7.4%6.3%——
Return on assets4.4%5.7%6.5%6.4%5.3%4.3%——
Free cash flow yield16.0%16.5%17.9%16.4%15.5%10.5%——
Revenue growth-15.5%-19.9%11.8%19.2%20.3%-33.6%——
Earnings growth-22.4%-15.6%6.8%35.5%21.9%-48.1%——
Current ratio1.92x1.76x2.52x2.09x1.98x1.70x——
Debt to equity—0.12x—0.00x0.05x0.12x0.17x0.16x
Equity ratio70.2%65.4%73.0%70.0%71.5%68.1%——
Interest coverage26.04x17.63x308.47x182.04x28.85x13.33x——
R&D as a share of sales18.5%16.4%17.4%13.9%13.7%12.5%——
Buybacks as a share of market value0.8%-0.7%3.6%-5.5%17.4%-17.7%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-8.9%1.7%1.6%
Operating income-6.2%1.3%-0.6%
Net income-11.2%2.9%-1.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin72.1%72.7%72.6%74.1%
Operating margin10.6%10.2%10.3%11.5%
Net margin9.7%9.7%9.4%10.4%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings26.620.125.325.721.526.416.914.619.128.1
Price to sales2.52.02.42.61.92.31.91.62.23.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 31 May 2024.

FY2024FY2023FY2020FY2019FY2018FY2017FY2016FY2015
Paid in the year0.3720.220.080.080.060.060.0670.083
  • 6-for-5 split · 24 Jun 2016
  • 6-for-5 split · 27 Jun 2014
  • 13-for-10 split · 20 Aug 2010
  • 6-for-5 split · 11 May 2009
  • 8-for-5 split · 7 May 2008
  • 1-to-1 reverse split · 16 Nov 2005

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.